Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, sales was SEK 4.75 million compared to SEK 4.92 million a year ago. Revenue was SEK 6.46 million compared to SEK 6.53 million a year ago. Net loss was SEK 39.2 million compared to SEK 39.07 million a year ago. Basic loss per share from continuing operations was SEK 0.61 compared to SEK 0.99 a year ago. Diluted loss per share from continuing operations was SEK 0.61 compared to SEK 0.99 a year ago.